Immunohistochemical staining of formalin fixed and paraffin embedded human colon cancer tissue sections using Anti-Erk1 antibody (RM470) at 1:100 dilution.
anti-p44 MAPK (Erk1), Rabbit Monoclonal (RM470)
REV-31-1362-00
Product group Antibodies
Overview
- SupplierRevMAb Biosciences
- Product Nameanti-p44 MAPK (Erk1), Rabbit Monoclonal (RM470)
- Delivery Days Customer10
- CertificationResearch Use Only
- ClonalityMonoclonal
- Scientific DescriptionExtracellular signal-regulated kinases 1 and 2 (also known as ERK1/2, p44/42, or MAPK3/1) belong to a family of conserved serine/threonine protein kinases known as mitogen-activated protein kinases (MAPKs) that are involved in many cellular programs such as proliferation, differentiation, motility and survival. The ERK1/2 signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors and cytokines. The primary activators of ERK1/2 are MEK1 and MEK2 which activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187 in ERK1 and ERK2, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1. ERK1/2 are negatively regulated by MAPK phosphatases as well as by chemical inhibitors of MEK. The ERK pathway is disrupted in many types of cancer and thus is an important target for diagnosis and treatment. - Recombinant Antibody. RM470 reacts to human Erk1 (p44-MAPK). Isotype: Rabbit IgG. Immunogen: A peptide corresponding to the C-terminus of human Erk1 (p44-MAPK). Applications: IHC, WB. Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. Extracellular signal-regulated kinases 1 and 2 (also known as ERK1/2, p44/42, or MAPK3/1) belong to a family of conserved serine/threonine protein kinases known as mitogen-activated protein kinases (MAPKs) that are involved in many cellular programs such as proliferation, differentiation, motility and survival. The ERK1/2 signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors and cytokines. The primary activators of ERK1/2 are MEK1 and MEK2 which activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187 in ERK1 and ERK2, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1. ERK1/2 are negatively regulated by MAPK phosphatases as well as by chemical inhibitors of MEK. The ERK pathway is disrupted in many types of cancer and thus is an important target for diagnosis and treatment.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203